Valneva's COVID-19 Vaccine Candidate Using Dynavax's Adjuvant Shows Positive Interim Results

Dynavax Technologies Corporation DVAX has announced that Valneva SE reported initial results from Part A of the Phase 1/2 trial evaluating Valneva's COVID-19 vaccine candidate, VLA2001, using Dynavax's CpG 1018 adjuvant.
The trial is being conducted in 153 healthy adults aged 18 to 55 years.
VLA2001 was generally safe and well-tolerated across all dose groups tested and was highly immunogenic with a seroconversion rate for S-protein binding IgG antibodies of 100% in the high dose group.
The IgG antibody response was highly correlated with neutralization titers in a micro-neutralization assay.
Valneva plans to initiate a pivotal, comparative immunogenicity Phase 3 clinical trial with the high dose formulation by the end of next month.
Dynavax developed CpG 1018 adjuvant to provide an increased vaccine immune response.
CpG 1018 adjuvant is used in Hepatitis B Vaccine approved by the FDA and the European Medicines Agency.
Price Action: DVAX shares are trading 4.4% higher at $10.28 on the last check Tuesday.